Outcomes Study Reports Use of MelaFind Reduced Benign

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Outcomes Study Reports Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for Melanoma

IRVINGTON, N.Y., Oct. 21, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq: MELA ), developer of MelaFind ® , a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), today announced that highly favorable results were obtained in a study using MelaFind to assess lesions in patients at risk for melanoma. The results were included in the 2013 Outcomes for Cleveland Clinic's Dermatology & Plastic Surgery Institute , which was recently released.

In the study, an initial cohort of 166 pigmented lesions on 30 patients were identified as suspicious by visual inspection and dermoscopy. Following the MelaFind data, 64 of those lesions were identified for biopsy and 102 were selected for continued observation. The report stated, "The results showed 61% of the clinically suspicious pigmented lesions in an at-risk population were deferred from biopsy, indicating that MelaFind analysis may prevent overly aggressive biopsy decisions. There may also be an overall improvement in biopsy risk." The study was conducted independently and not sponsored by MELA Sciences, Inc.

"Using the MelaFind system, doctors at this hospital achieved measurable success that adds to our growing body of evidence showing the MelaFind system can reduce health care costs when treating what is today one of the fastest growing cancers," said Rose Crane, MELA Sciences President and CEO. "There are a number of challenges in detecting melanoma and the doctors at this institution using MelaFind exemplify the positive shift in healthcare outcomes that can be achieved when innovative technology is implemented and its progress is quantified."

About MelaFind www.melafind.com

MelaFind® is intended to provide a dermatologist with a software-driven image analysis of clinically irregular pigmented moles when they choose to obtain additional info to help decide whether or not to biopsy (at the most curable and cost-effective stage). MelaFind® is both FDA Pre-Market Approved (PMA) for the U.S. and has CE Marking certification for the European Union.

The MelaFind® system utilizes innovative software-driven technology and state-of-the-art 3-D imaging to non-invasively extract data 2.5 mm below the skin surface from patient's clinically irregular pigmented moles and objectively analyzes them with proprietary algorithms. MelaFind provides important additional perspective to physicians to help them better understand the structural disorganization of a patient's pigmented irregular moles (before cutting the skin) during the evaluation and diagnosis process for melanoma.

About MELA Sciences, Inc. www.melasciences.com

MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for its flagship product, MelaFind®.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and may contain words such as "seeks," "look forward," and "there seems" that suggest future events or trends. These statements are based on our current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from our expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. MELA Sciences assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.melasciences.com .

Media Deanne Eagle Planet Communications (917) 837-5866 Diana Garcia Redruello MELA Sciences, Inc. 212-518-4226 Investors Andrew McDonald, Ph.D LifeSci Advisors, LLC 646-597-6987

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 5

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 174

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 47

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Cavalry’s I-70 Towing Bet Starts With Columbus Base

Updated Category News Views 71

A jackknifed tractor-trailer does not care about a private-equity playbook. It needs the right rig, a trained crew and somebody arriving before a blocked highway turns into an all-day mess. That unglamorous reality is exactly why Southfield Capital’s new Cavalry Fleet Services platform deserves a closer look. Commercial towing is a necessary, hard-edged local business...

Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation

Updated Category News Views 81

Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 138

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 157

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 25

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading

Top 5 Most Recently Viewed Articles

Kering Faces Challenges as Goldman Sachs Downgrades Rating

Updated Category News Views 108

Kering's stock price took a serious hit back in early 2024 after Goldman Sachs slapped a "sell" rating on the luxury group's shares. At the time, they were sitting at €249.50, reflecting a sharp decline of about 2.9%. Desks were buzzing over this downgrade, particularly because it pointed fingers at Gucci—a brand that's been Kering’s cash cow for years. Kering's...

Continue Reading
Treatment.com AI to Showcase Innovations at Cantech Conference

Updated Category News Views 174

Treatment.com AI, a player in healthcare tech, geared up for its big moment at the Cantech Letter Investment Conference back in 2024. The spotlight was on Dr. Essam Hamza, CEO of the firm, who was set to reveal how their advanced AI-driven solutions were set to transform patient care. You could almost hear traders buzzing about the potential impact on share prices as the...

Continue Reading
Bombardier Celebrates First Challenger 3500 Deliveries

Updated Category News Views 408

Landmark Deliveries of the Challenger 3500 Bombardier proudly announces a significant achievement with the beginning of deliveries of three state-of-the-art Challenger 3500 aircraft to Aloula Aviation. This event marks a milestone as these are the first Challenger 3500 aircraft registered in Saudi Arabia, showcasing Bombardier's dedication to enhancing global aviation....

Continue Reading
Siili Solutions Shares Repurchase Update for 2025

Updated Category News Views 167

Overview of Siili Solutions Plc's Share Repurchase Siili Solutions Plc is taking significant steps to enhance shareholder value through strategic share buybacks. Recently, they announced a share repurchase on June 26, 2025, which adds to their ongoing efforts in the market. This initiative is an essential part of their financial strategy, showing a commitment to returning...

Continue Reading
Xiaomi's YU7 SUV Surpasses Tesla Model Y in China Sales

Updated Category News Views 236

Xiaomi's YU7 SUV Emerges as a Strong Contender Xiaomi Corp. has made a significant impact in the electric vehicle sector, particularly in January when their YU7 SUV surpassed Tesla Inc.'s Model Y in sales within the Chinese market. The impressive sales figures highlight Xiaomi's growing influence in the automotive landscape. Strong Sales Performance of the YU7 During the...

Continue Reading